Últimas noticias sobre Heron Therapeutics (NASDAQ:HRTX) Bolsa

HERON THERAPEUTICS INC

Heron Therapeutics

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Heron Therapeutics Inc

WIIM

HRTX

Heron Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) affirms FY2025 sales outlook from $153.00 million-$163.00 million to $153.00 million-$163.00 million vs $157.27 million estimate.

News

Guidance

Heron Therapeutics Affirms FY2025 Sales Guidance of $153.00M-$163.00M vs $157.27M Est

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 200 percent. This is a 150 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $38.90 million which beat the analyst consensus estimate of $37.42 million by 3.97 percent. This is a 12.21 percent increase over sales of $34.67 million the same period last year.

Earnings

Earnings Beats

Heron Therapeutics Q1 EPS $0.01 Beats $(0.01) Estimate, Sales $38.90M Beat $37.42M Estimate

Legal

Heron Therapeutics Enters Settlement Agreement With Mylan To Resolve Patent Litigations In US District Court For The District Of Delaware Related To CINVANTI And APONVIE

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and maintains $4 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Heron Therapeutics, Maintains $4 Price Target

Heron Therapeutics shares are trading higher following better-than-expected Q4 financial results.

Heron Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

Financial Guidance for 2025&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Item</td>
<td colspan="4" rowspan="1">
2025 Full-Year Guidance for Net Revenue and Adjusted EBITDA
(in millions)
</td>
</tr>
<tr>
<td colspan="2" rowspan="1">
&nbsp;
Net Revenue
</td>
<td colspan="1" rowspan="1">$153.0</td>
<td colspan="1" rowspan="1">
&nbsp;
to
</td>
<td colspan="1" rowspan="1">$163.0</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$0.0</td>
<td colspan="1" rowspan="1">to</td>
<td colspan="1" rowspan="1">$8.0</td>
</tr>
</tbody>
</table>
</figure>

Biotech

Health Care

General

Heron Therapeutics Expects 2025 Sales Of $153M-$163M Versus Consensus Of $160.633M

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.03) by 166.67 percent. This is a 128.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $40.78 million which beat the analyst consensus estimate of $37.37 million by 9.14 percent. This is a 19.13 percent increase over sales of $34.23 million the same period last year.

Heron Therapeutics Q4 2024 GAAP EPS $0.02 Beats $(0.03) Estimate, Sales $40.78M Beat $37.37M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

<h3>Gainers</h3>
<ul>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares rose 225.5% to $5.24 during Wednesday's pre-market session. The company's market cap stands at $14.2 million. </li>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock rose 66.94% to $1.97. The market value of their outstanding shares is at $299.6 million. </li>
<li>Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) stock moved upwards by 62.36% to $18.12. The market value of their outstanding shares is at $612.6 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock increased by 32.97% to $0.48. The market value of their outstanding shares is at $24.5 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 26.42% to $17.7. The company's market cap stands at $38.4 million. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares increased by 21.0% to $0.2. The company's market cap stands at $7.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock decreased by 74.7% to $0.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $21.1 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock fell 12.55% to $20.99. The company's market cap stands at $30.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares fell 11.73% to $0.48. The company's market cap stands at $4.2 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock fell 9.26% to $0.36. The market value of their outstanding shares is at $6.0 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares fell 9.04% to $0.74. The company's market cap stands at $3.7 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 8.7% to $0.6. The company's market cap stands at $17.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BMRA

CCRN

CYCN

CYTH

ERNA

FBRX

QNRX

RLMD

VIRX

WINT

XCUR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Heron Therapeutics shares are trading higher. Needham reiterated a Buy rating on the stock.

Shares of Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter <a href="https://www.benzinga.com/news/earnings/24/12/42302752/marvell-technology-stock-climbs-after-better-than-expected-q3-results-strong-q4-guidance">guidance above estimates</a>.
Marvell Technology reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 41 cents. Quarterly revenue came in at $1.52 billion, which beat the consensus estimate of $1.46 billion and is an increase over sales of $1.42 billion from the same period last year.
Marvell Technology shares jumped 12.6% to $108.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) gained 151.8% to $0.7953 in pre-market trading. CN Energy received extension from Nasdaq to meet minimum bid price requirement until May 2025.</li>
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) rose 81.5% to $0.5770 in pre-market trading after dipping 6% on Tuesday.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) gained 80.5% to $2.13 in pre-market trading. Heron Therapeutics said US District Court ruled in its favor in patent litigation against Fresenius Kabi with respect to CINVANTI Injectable Emulsion.</li>
<li>Viracta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) gained 50.2% to $0.2445 in pre-market trading.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) gained 22.8% to $0.2015 in pre-market trading after gaining 12% on Tuesday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 21.4% to $17.00 in pre-market trading after tumbling 37% on Tuesday.</li>
<li>NFT Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MI#NYSE">MI</a>) gained 23.3% to $5.350 in pre-market trading after gaining 8% on Tuesday.</li>
<li>Pure Storage, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) rose 22.3% to $65.50 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance above estimates.</li>
<li>Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) gained 13% to $374.38 in pre-market trading. The company posted downbeat earnings for its third quarter, while sales topped estimates. The company also said it sees full-year 2025 revenue of $37.8 billion to $38 billion and full-year adjusted earnings to be between $9.98 and $10.03 per share.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) shares tumbled 44.4% to $6.65 in pre-market trading after jumping 82% on Tuesday.</li>
<li>Bolt Projects Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) declined 22.6% to $0.5031 in pre-market trading after declining 8% on Tuesday. The company recently announced a private placement of 1.06 million shares for $360K in gross proceeds.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares fell 17.3% to $0.4550 in pre-market trading as the company announced a 1-for-15 reverse stock split.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) fell 16.7% to $4.07 in pre-market trading. Cheetah Net Supply Chain Service shares jumped 160% on Tuesday after the company announced the acquisition of TW &amp; EW Services in a cash and stock mixed transaction valued at $1 million.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) shares fell 13.4% to $14.95 in pre-market trading. ZJK Industrial shares jumped 172% on Tuesday after the company announced it received a request to produce samples for one of NVIDIA&#8217;s upcoming liquid cooling manifold projects.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) fell 12.7% to $12.36 in pre-market trading. Intuitive Machines priced its upsized $110.0 million offering of shares of its Class A common stock and concurrent private placement.</li>
<li>ESGL Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESGL#NASDAQ">ESGL</a>) fell 11.6% to $1.30 in pre-market trading after declining around 6% on Tuesday.</li>
<li>Volato Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NASDAQ">SOAR</a>) dipped 10.1% to $0.3290 in pre-market trading. Volato Group shares jumped 65% on Tuesday after the company unveiled a patent-pending Bitcoin mining technology.</li>
<li>Gaotu Techedu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) shares dipped 9.7% to $2.69 in pre-market trading following third-quarter results.</li>
<li>Crescent Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NASDAQ">CRGY</a>) fell 5.4% to $14.32 in today's pre-market trading. Crescent Energy Company priced its upsized public offering of 21.5 million Class A common shares at $14/share.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42293707/jim-cramer-prefers-this-delivery-giant-over-ups">Jim Cramer Prefers FedEx Over This Delivery Giant That &#8216;Screwed Up A Lot Of Holiday Seasons&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

BSLK

CNEY

CRGY

CTNT

ENSC

ESGL

GSX Techedu Inc. American Depositary Shares

GOTU

HTOO

LUNR

MRVL

ORIS

PSTG

SOAR

TANH

Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

The district court decision concludes the litigation initiated in July 2022 in response to Fresenius' submission of an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval of a generic version of CINVANTI.&nbsp;
As a result of the decision, Heron will seek an order from the Court prohibiting Fresenius from launching its generic CINVANTI until after the expiration of the patents in 2035. This decision is subject to appeal.

Heron Therapeutics Says US District Court Ruled In Its Favor In Patent Litigation Against Fresenius Kabi With Respect To CINVANTI Injectable Emulsion

Comments

Heron Therapeutics

Noticias

Últimas noticias sobre Heron Therapeutics (NASDAQ:HRTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL